Skip to main content

Atea Pharmaceuticals, Inc.

corporate_fare Company Profile

Atea Pharmaceuticals, Inc.

AVIR·NASDAQ·Life Sciences·CIK 0001593899

We are a late-stage clinical biopharmaceutical company focused on discovering, developing, and commercializing new, orally administered antiviral drugs for serious viral diseases. Our expertise is in antiviral drug development, medicinal chemistry, biochemistry, and virology. Our current product pipeline includes bemnifosbuvir and ruzasvir, a regimen we believe could improve the standard of care for hepatitis C virus (HCV) infection. We also have AT-587, which we believe could be the first direct-acting antiviral for chronic hepatitis E virus (HEV) infection, especially for immunocompromised patients. Our HCV development program aims to offer bemnifosbuvir and ruzasvir as a distinct pan-genotypic, protease inhibitor-free, short-duration treatment for HCV-infected patients, if successfully developed and approved. We believe a new, easily prescribable treatment regimen would benefit the current HCV population, which is mainly young (20-49 years old) and non-cirrhotic, and would significantly improve the current standard of care. Currently, there are no short-course (8-week) nucleotide inhibitor-based, pan-genotypic HCV treatment regimens. Clinical and nonclinical studies, including a global Phase 2 clinical trial with 275 HCV-infected patients, have shown that bemnifosbuvir and ruzasvir have high potency and are well tolerated. These studies also indicate a low risk for drug-drug interactions with many common medications, including proton pump inhibitors, and can be taken with or without food. We believe this profile would significantly improve the current standard of care, if approved. Our global HCV Phase 3 program includes two randomized, open-label studies: C-BEYOND, with clinical trial sites in the US and Canada, and C-FORWARD, with sites in countries outside North America.

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 12 items for AVIR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 12 most recent items scored 7 or higher, the top rating is 9/10, with 5 rated 8 or above. Recent SEC coverage for AVIR spans 10-Q, 8-K, 10-K.

Recent high-impact activity:

  • Atea 10-Q: $110.5M Nine-Month Loss, $191.2M Cash, and a New CAO Resignation
  • Atea Posts Q3 2026 Results; $200M Hercules Facility Extends Cash Runway to Mid-2028
  • Atea Signs $200M Hercules Term Loan, Draws $65M at Close
  • Atea's C-BEYOND Hits Non-Inferiority: 93.9% SVR vs Epclusa, $2.5B HCV Market in Sight
  • Atea's Hepatitis C Drug Hits Phase 3 Goal, Matching Standard of Care

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$158.35M
Diluted EPS
-$1.94
Op. Cash Flow
-$132.03M
Operating Income
-$180.89M
Cash & Equivalents
$95.71M
Debt / Equity
0.00×
Shares Outstanding
78.13M sh
Source: 10-K · filed 2026-03-05 · accession 0001193125-26-094159

Short Interest & Short Volume

9.55 days to cover

FINRA reported short interest of 3,008,126 shares in AVIR as of the October 30, 2026 settlement, a 2.0% decrease from the prior period — about 9.6 days to cover at its recent average daily volume. On November 20, 2026, 39.1% of AVIR volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,008,126 shares as of October 30, 2026
Change vs prior period▼ 2.0%
Days to cover9.55 at avg daily volume of 315,089
Daily short volume (FINRA facilities)39.1% of 129,964 shares on November 20, 2026
5-day average short volume53.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$3.97 +0.25% today
52-week range · as of 2026-11-09 $2.87 – $6.45
Market cap
$318M
Volume
416.5K (1.3× avg)
3-mo avg 315K
Live data · 2026-11-21 23:13 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed AVIR - Latest Insights

AVIR
Nov 09, 2026, 5:01 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.41
Real-time Price: $3.97 info
Change: -$0.440 (-10%) info
Market Cap: $318.004M info
AVIR
Nov 09, 2026, 4:17 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.41
Real-time Price: $3.97 info
Change: -$0.440 (-10%) info
Market Cap: $318.004M info
AVIR
Nov 09, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.39
Real-time Price: $3.97 info
Change: -$0.420 (-10%) info
Market Cap: $318.004M info
AVIR
Aug 12, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.06
Real-time Price: $3.97 info
Change: -$1.09 (-22%) info
Market Cap: $318.004M info
AVIR
Jul 28, 2026, 7:41 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $4.87
Real-time Price: $3.97 info
Change: -$0.900 (-18%) info
Market Cap: $318.004M info
AVIR
Jul 14, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.75
Real-time Price: $3.97 info
Change: -$0.782 (-16%) info
Market Cap: $318.004M info
AVIR
Jun 25, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.51
Real-time Price: $3.97 info
Change: -$0.540 (-12%) info
Market Cap: $318.004M info
AVIR
May 27, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.39
Real-time Price: $3.97 info
Change: -$0.420 (-10%) info
Market Cap: $318.004M info
AVIR
May 12, 2026, 4:45 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $5.50
Real-time Price: $3.97 info
Change: -$1.53 (-28%) info
Market Cap: $318.004M info
AVIR
May 12, 2026, 4:27 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $5.50
Real-time Price: $3.97 info
Change: -$1.53 (-28%) info
Market Cap: $318.004M info
AVIR
Mar 05, 2026, 4:50 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $5.45
Real-time Price: $3.97 info
Change: -$1.48 (-27%) info
Market Cap: $318.004M info
AVIR
Jan 08, 2026, 9:05 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.48
Real-time Price: $3.97 info
Change: +$0.490 (+14%) info
Market Cap: $318.004M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets